Recent progress on nanoparticle-based drug delivery systems for cancer therapy

Xin, Yanru; Yin, Mingming; Zhao, Liang; Meng, Fanling; Luo, Liang

doi:10.20892/j.issn.2095-3941.2017.0052

Cited by 229 publications

(112 citation statements)

References 80 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…Nanodrug delivery systems have always been a research hotspot for targeted therapy. All kinds of nanoparticles made by proteins, macromolecules or other materials have been shown to have positive therapeutic value (Xin et al, 2017;Zhang et al, 2019a,b). However, the possible biological toxicity and sensitization of medical macromolecule polymers used in drug delivery systems need to be solved before they can be clinically applied (Nouman et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Ultrasound-responsive highly biocompatible nanodroplets loaded with doxorubicin for tumor imaging and treatment in vivo

et al. 2020

View full text Add to dashboard Cite

2020) Ultrasound-responsive highly biocompatible nanodroplets loaded with doxorubicin for tumor imaging and treatment in vivo, Drug Delivery, 27:1, 469-481, ABSTRACTAs an injectable anticancer drug delivery system, the biological safety of nanocarriers is the most important prerequisite for their clinical application. The objective of our study was to synthesize special ultrasound-responsive highly biocompatible chitosan nanodroplets (BCNDs), observe their spatiotemporally control the delivery of doxorubicin (DOX) in vivo. The experimental results showed that the BCNDs were successfully prepared with high biosafety in vivo and great ultrasound imaging ability. DOX-BCNDs promoted the anticancer effects of DOX in vivo and inhibited the development of tumors. They also reduced the side effects to the heart and kidneys. In conclusion, BCNDs are a new type of smart nanocarrier with high biocompatibility and efficacy have great potential to be used in the clinic. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

Ultrasound-responsive highly biocompatible nanodroplets loaded with doxorubicin for tumor imaging and treatment in vivo

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A small phase I pilot showed that NC-6004 was acknowledged by carcinoma patients that were affected by colorectal carcinoma, upper oesophageal carcinoma, and lung carcinoma [69]. The Genexol-PM formulation was a micellar PTX nanoformulation formulated from PEG with polylactic acid [68,134,135]. Preclinical in vivo trials with Genexol-PM formulation exhibited a threefold increase in average dissolution time and a significantly improved antineoplastic efficacy as compared with clinical paclitaxel [69].…”

Section: Nanomicelles In Clinical Evaluationsmentioning

confidence: 99%

Nanodrug Delivery Systems for the Treatment of Ovarian Cancer

Pantshwa

Kondiah

Choonara

et al. 2020

Cancers

View full text Add to dashboard Cite

Despite advances achieved in medicine, chemotherapeutics still has detrimental side effects with ovarian cancer (OC), accounting for numerous deaths among females. The provision of safe, early detection and active treatment of OC remains a challenge, in spite of improvements in new antineoplastic discovery. Nanosystems have shown remarkable progress with impact in diagnosis and chemotherapy of various cancers, due to their ideal size; improved drug encapsulation within its interior core; potential to minimize drug degradation; improve in vivo drug release kinetics; and prolong blood circulation times. However, nanodrug delivery systems have few limitations regarding its accuracy of tumour targeting and the ability to provide sustained drug release. Hence, a cogent and strategic approach has focused on nanosystem functionalization with antibody-based ligands to selectively enhance cellular uptake of antineoplastics. Antibody functionalized nanosystems are (advanced) synthetic candidates, with a broad range of efficiency in specific tumour targeting, whilst leaving normal cells unaffected. This article comprehensively reviews the present status of nanosystems, with particular emphasis on nanomicelles for molecular diagnosis and treatment of OC. In addition, biomarkers of nanosystems provide important prospects as chemotherapeutic strategies to upsurge the survival rate of patients with OC.

show abstract

“…Chemical neuromodulation techniques use either implantable devices, focused ultrasound, lipophilic vesicles, or nanoparticle formulations to overcome the blood-brain barrier and ensure delivery of adequate chemical concentrations to targeted neural compartments (see [76] and references therein). The state-of-the-art solutions for brain pathologies involve the application of nanoparticles synthesized from various materials (e.g., polymers, lipids, and viruses) [77]- [79]. By using either passive or active targeting strategies, nanoparticles can increase the intracellular concentration of drugs in neurons via receptor-mediated endocytosis while preventing toxicity to other cells.…”

Section: A State-of-the-artmentioning

confidence: 99%

Synaptic Communication Engineering for Future Cognitive Brain–Machine Interfaces

Veletić

Balasingham

2019

Proc. IEEE

View full text Add to dashboard Cite

Disease-affected nervous systems exhibit anatomical or physiological impairments that degrade processing, transfer, storage, and retrieval of neural information leading to physical or intellectual disabilities. Brain implants may potentially promote clinical means for detecting and treating neurological symptoms by establishing direct communication between the nervous and artificial systems. Current technology can modify neural function at the supracellular level as in Parkinson's disease, epilepsy, and depression. However, recent advances in nanotechnology, nanomaterials, and molecular communications have the potential to enable brain implants to preserve the neural function at the subcellular level which could increase effectiveness, decrease energy consumption, and make the leadless devices chargeable from outside the body or by utilizing the body's own energy sources. In this study, we focus on understanding the principles of elemental processes in synapses to enable diagnosis and treatment of brain diseases with pathological conditions using biomimetic synaptically interactive brain-machine interfaces. First, we provide an overview of the synaptic communication system, followed by an outline of brain diseases that promote dysfunction in the synaptic communication system. We then discuss technologies for brain implants and propose future directions for the design and fabrication of cognitive brain-machine interfaces. The overarching goal of this paper is to summarize the status of engineering research at the interface between technology and the nervous system and direct the ongoing research towards the point where synaptically interactive brain-machine interfaces can be embedded in the nervous system.

show abstract

Recent progress on nanoparticle-based drug delivery systems for cancer therapy

Cited by 229 publications

References 80 publications

Ultrasound-responsive highly biocompatible nanodroplets loaded with doxorubicin for tumor imaging and treatment in vivo

Ultrasound-responsive highly biocompatible nanodroplets loaded with doxorubicin for tumor imaging and treatment in vivo

Nanodrug Delivery Systems for the Treatment of Ovarian Cancer

Synaptic Communication Engineering for Future Cognitive Brain–Machine Interfaces

Contact Info

Product

Resources

About